Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Bayer (ETR: BAYN) Q1 beat lifts shares as Supreme Court Roundup ruling looms
Bayer just beat Q1 consensus by 19%. But the bigger question is whether the Supreme Court hands the company its Roundup endgame in six weeks.
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
How AlloNK could challenge autologous CAR-T approaches in difficult autoimmune diseases
Can AlloNK challenge autoimmune CAR-T therapies? Explore what Artiva Biotherapeutics, Inc.’s latest data means for the future of cell therapy.
What REYOBIQ’s Phase 1 data means for the future of CNS-directed radiopharmaceutical platforms
What does REYOBIQ’s Phase 1 data reveal about the future of CNS-targeted radiopharmaceuticals? Explore the broader neuro-oncology implications.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
ACROBiosystems just removed a quiet bottleneck in drug discovery. Will biopharma buyers notice?
Biopharma wants faster R&D, but compliance still slows labs. ACROBiosystems is turning HEK293 licensing into a workflow advantage.
Can Ampligen improve immunotherapy durability in recurrent ovarian cancer treatment?
Can AIM ImmunoTech Inc.’s Ampligen improve immunotherapy durability in ovarian cancer? Explore the Phase 2 data and industry impact.
Why neuroinflammation and systemic inflammation are becoming central targets in traumatic brain injury research
Why are neuroinflammation and systemic inflammation becoming major targets in traumatic brain injury research? Explore the industry shift now.
Wenda Pharma’s NHWD-870 breakthrough tag puts rare NUT carcinoma therapy in sharper focus
A rare cancer has few targeted options. Wenda Pharma’s NHWD-870 now tests whether China can move faster in precision oncology.